focus -WSS

focus

author：explore 2025-10-01 20:16:08 - browse：6

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

The Food and Drug Administration rejected an Alnylam Pharmaceuticals’ therapy for an increasingly prevalent heart disease, the company said Monday, citing insufficient evidence that the treatment meaningfully improved patients’ lives.

Alnylam will no longer seek approval of its drug, an intravenous medicine sold as Onpattro, for people with ATTR-CM, a progressive disease that leads to heart failure if left untreated. The company is in the late stages of development of an updated version of Onpattro that can be administered through a small needle under the skin. Data from a pivotal study, expected next year, would support an FDA application for that treatment.

For Onpattro, a 12-month clinical trial found that the treatment outperformed placebo on a test of how far patients could walk over the course of six minutes, suggesting the medicine slowed down the progression of ATTR-CM. Onpattro also improved patients’ scores on a quality-of-life questionnaire compared to placebo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Lasker Awards 2023: Winners in biomedical research

WSS

Drug for rare kidney disease narrowly misses mark in clinical trial

White House Covid adviser calls on docs to combat misinformation

Grad students accuse University of California of wage theft

David Liu startup to focus on CRISPR delivery

The unintended consequences of overturning Roe v. Wade

It's been 20 years since Dolly the sheep. Where's my clone?

entertainment

focus

hotspot

Peter Hotez and the public health issue of online harassment

Grad students accuse University of California of wage theft

Novavax promises a turnaround & Lilly roils the obesity market

Senators: Long

23andMe had bad news about my health. I wish a person had delivered it

Chamber of Commerce, DOJ clash in court over drug prices

Jerome Adams on the need for new antivirals for Covid

Fed up with FDA, ALS advocates consider a take

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Chamber of Commerce, DOJ clash in court over drug prices

focus

EpiPen alternative approval delay highlights citizen petition issue

House panel takes first step toward fixing drug shortages

Eli Lilly CEO gives to Mike Pence presidential super PAC

What happened to the House vote on health price transparency?

David Liu startup to focus on CRISPR delivery

Information blocking fines are now fair game in health care

entertainment

hotspot

explore

focus